Guest Commentary

Guest Commentary

An ASH Annual Meeting Post-Vivum

“So, what did you learn from ASH?” asked my advisor a couple of weeks after I returned from my first American Society of Hematology...

#SHEmatology and #WOMANcology: Encouraging Women to Explore Careers and Leadership in Hematology and Oncology

Over the past 50 years, women in medicine have gained greater representation, with each generation of trainees moving closer to gender parity. The number...

Advice for the Graduating Hematologist

When I was asked to collect some thoughts to share with hematology/oncology trainees upon completion of their fellowship, I thought back on my experiences...

The Superwarfarin Chronicles

Over the past decade, the use of synthetic cannabinoids/marijuana has increased. These products generally consist of plant material sprayed with chemicals that can interact...

The Roadmap Forward in Follicular Lymphoma: Time for a Precision Approach

Over the past two decades, improved diagnostic accuracy and novel therapeutic approaches have resulted in profound improvements in overall survival in patients with follicular...

The Present and Future Multiple Myeloma Landscape

The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...
Advertisement

Current Issue

January 2019 Annual Meeting Edition

This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.